VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

This study has been completed.
Sponsor:
Information provided by:
International Extranodal Lymphoma Study Group (IELSG)
ClinicalTrials.gov Identifier:
NCT00210327
First received: September 13, 2005
Last updated: July 21, 2009
Last verified: July 2009

September 13, 2005
July 21, 2009
July 2005
November 2008   (final data collection date for primary outcome measure)
Antitumor activity, in terms of overall response rate (ORR) i.e. sum of complete and partial responses
Same as current
Complete list of historical versions of study NCT00210327 on ClinicalTrials.gov Archive Site
  • Safety, as acute and long-term toxicity
  • Response duration (RD) (time to relapse or progression) in responders
  • Progression-free survival (PFS) (time to disease progression or death from lymphoma) in all patients
Same as current
Not Provided
Not Provided
 
VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy
Phase II Study of VELCADE in Patients With Extranodal Marginal Zone B-cell Lymphoma of MALT-type Pretreated With Prior Systemic Therapy Regimen (X05142)

The primary objective of this study is to assess the antitumor activity (in terms of overall response rate - ORR - i.e. sum of complete and partial responses)of bortezomib in pretreated MALT lymphomas with one prior sistemic therapy regimen

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Lymphoma, Mucosa-Associated Lymphoid Tissue
Drug: Bortezomib (drug)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
33
April 2009
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. histologically proven d MALT lymphoma at any extranodal site
  2. any stage (Ann Arbor I-IV)
  3. relapsed or refractory disease pretreated with prior chemotherapy regimens +/- anti-CD20 immunotherapy or prior anti-CD20 immunotherapy (any number of prior lines of therapy)
  4. no evidence of histologic transformation to a high grade lymphoma
  5. measurable or evaluable disease
  6. age > 18 years
  7. full recovery from previous therapy, with life expectancy of at least 6 months
  8. ECOG performance status 0-2
  9. for primary gastric localized H. pylori-positive disease at diagnosis:

    1. persistent disease 1 year after documented H. pylori infection eradication
    2. clinical, endoscopic (or histologic) evidence of progression at any time after H. pylori infection eradication
  10. no prior chemotherapy, immunotherapy or radiotherapy in the last 6 weeks
  11. no corticosteroids during the last 4 weeks, unless prednisone chronically administered at a dose <20 mg/day for indications other than lymphoma or lymphoma-related symptoms
  12. adequate renal function (calculated or measured creatinine clearance >30 mL/minute), liver function (ASAT/ALAT <2,5 upper normal, total bilirubin <2,5x upper normal) and bone marrow function
  13. no evidence of active opportunistic infections
  14. no known HIV infection
  15. no active HBV and/or HCV infection
  16. no serious medical illness likely to interfere with participation in this clinical study
  17. voluntary written informed consent before performance of any study-related procedure
  18. female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (ie, a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. Male subject agrees to use an acceptable method for contraception for the duration of the study

Exclusion Criteria:

  1. prior diagnosis of neoplasm within 5 years, except cervical intraepithelial neoplasia type 1(CIN1) or localized non-melanomatous skin cancer
  2. other investigational drugs within 14 days before enrollment
  3. evidence of symptomatic central nervous system (CNS) disease
  4. severe impairment of bone marrow function (ANC <1.0x109/L, PLT <30x109/L within 14 days before enrollment), unless due to lymphoma involvement
  5. evidence of ≥ grade 2 peripheral neuropathy within 14 days before enrollment
  6. known hypersensitivity to bortezomib, boron or mannitol
  7. pregnant or lactating status, confirmation that the subject is not pregnant must be established by a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women
  8. any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00210327
IELSG25A
Yes
International Extranodal Lymphoma Study Group (IELSG), IELSG
International Extranodal Lymphoma Study Group (IELSG)
Not Provided
Study Chair: Franco Cavalli, MD International Extranodal Lymphoma Study Group
International Extranodal Lymphoma Study Group (IELSG)
July 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP